CD8A and breast carcinoma: Our previous study has found that METTL3 knockdown in a breast cancer mouse model enhanced PD-1 immunotherapy efficacy by improving CD8+ T cell infiltration and reducing immunosuppressive cells, thereby promoting an anti-tumor immune environment (11).